SIRT5 and fatty liver disease: Malonyl-CoA is elevated in skeletal muscle and liver from obese rats and in muscle biopsies from obese and T2D patients, and liver overexpression of SIRT5 enhances glycolysis in hepatocytes and inhibits gluconeogenesis, reducing hepatic triglycerides content of hepatic steatosis [129].